Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals

被引:0
作者
Van Deun, K [1 ]
Van Cauteren, H [1 ]
Vandenberghe, J [1 ]
Canning, M [1 ]
Vanparys, P [1 ]
Coussement, W [1 ]
机构
[1] Janssen Res Fdn, Dept Toxicol, B-2340 Beerse, Belgium
关键词
carcinogenicity; genotoxic; non-genotoxic; short-term tests; rodent bioassay; risk assessment; transgenic mice;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hundreds of pharmaceuticals have been reported to give a positive result in the standard "Chronic Bioassay", which consists of an 18 to 24 month daily administration of the test compound in mice and rats. This is in contrast with 20 pharmaceuticals, which are known to be carcinogenic to humans. The high incidence of apparently false-positive results in the Chronic Bioassy may be related to differences in mechanism of pharmacological action between rodents and humans, but also to the very high dose levels that have to be administered to rodents in accordance to regulatory guidelines. Lack of relevance to man therefore often has to be demonstrated by additional mechanistic studies. Based upon the deficiencies of the Chronic Bioassay and on the increased knowledge on cellular and molecular mechanisms involved in carcinogenicity, extensive discussions have recently taken place between regulatory agencies and industry associations at the occasion of International Conferences on Harmonization (ICH). These discussions have resulted in the possibility to use alternative short-to-medium-term carcinogenicity models in combination with a single two-year carcinogenicity study for evaluation of carcinogenicity. A description of these models is provided in this review as well as possible strategies for carcinogenicity testing and evaluation in the future.
引用
收藏
页码:215 / 233
页数:19
相关论文
共 45 条
[1]   CARCINOGENS ARE MUTAGENS - SIMPLE TEST SYSTEM COMBINING LIVER HOMOGENATES FOR ACTIVATION AND BACTERIA FOR DETECTION [J].
AMES, BN ;
DURSTON, WE ;
YAMASAKI, E ;
LEE, FD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (08) :2281-2285
[2]   THE AGE DISTRIBUTION OF CANCER AND A MULTI-STAGE THEORY OF CARCINOGENESIS [J].
ARMITAGE, P ;
DOLL, R .
BRITISH JOURNAL OF CANCER, 1954, 8 (01) :1-12
[3]   Alternatives to the 2-species bioassay for the identification of potential human carcinogens [J].
Ashby, J .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1996, 15 (03) :183-202
[4]   PREDICTION OF RODENT CARCINOGENICITY FOR 44 CHEMICALS - RESULTS [J].
ASHBY, J ;
TENNANT, RW .
MUTAGENESIS, 1994, 9 (01) :7-15
[5]  
BERENBLUM I, 1974, CARCINOGENESIS BIOL
[6]   A CRITIQUE OF THE USE OF THE MAXIMUM TOLERATED DOSE IN BIOASSAYS TO ASSESS CANCER RISKS FROM CHEMICALS [J].
CARR, CJ ;
KOLBYE, AC .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1991, 14 (01) :78-87
[7]   Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals [J].
Contrera, JF ;
Jacobs, AC ;
DeGeorge, JJ .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 25 (02) :130-145
[8]  
DAVIES TS, 1995, J AM COLL TOXICOL, V14, P90, DOI 10.3109/10915819509008684
[9]   THE RODENT CARCINOGENICITY BIOASSAY PRODUCES A SIMILAR FREQUENCY OF TUMOR INCREASES AND DECREASES - IMPLICATIONS FOR RISK ASSESSMENT [J].
DAVIES, TS ;
MONRO, A .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1994, 20 (03) :281-301
[10]  
DAVIES TS, 1996, FUNDAM APPL TOXICO S, V30, P201